Researchers found that Akkermansia muciniphila boosts lung-specific antiviral immunity against SARS-CoV-2 in mice by modulating the gut–lung axis. This commensal gut bacterium shows promise as a potential biomarker and biotherapeutic candidate for COVID-19 and other respiratory infections.